☆ 4.6 Article

A new tumorgraft panel to accelerate precision medicine in prostate cancer

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Endocrinology & Metabolism

RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer

Lauren Brady et al.

Summary: Neuroendocrine prostate cancer is a heterogeneous subtype with poor prognosis and limited treatment options. The study of tumor microenvironment and signaling pathways has provided insights into the biology of this subtype and suggested potential therapeutic approaches, including combination immunotherapies. However, further research is needed to fully understand and exploit the heterogeneity of tumor cells and the microenvironment for effective treatment strategies.

JOURNAL OF ENDOCRINOLOGY (2023)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Targeting cancer metabolism in the era of precision oncology

Zachary E. Stine et al.

Summary: In the past century, there have been significant advancements in targeting cancer metabolism, but progress in the past decade has been limited. Some metabolism-based drugs for cancer have been successfully developed and are in clinical trials. However, consideration of the metabolism of non-cancer cells is crucial for successful treatment of cancer.

NATURE REVIEWS DRUG DISCOVERY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer

Lingfan Xu et al.

Summary: Advanced and aggressive prostate cancer depends on glutamine for survival and proliferation. Inhibition of glutaminase 1 has shown therapeutic effect, but leads to therapy resistance. This study reveals the importance of both glutamine carbon and nitrogen pathways, and the existence of a reciprocal feedback mechanism.

ONCOGENE (2022)

添加到收藏夹

Review Oncology

Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?

Gio Fidelito et al.

Summary: Prostate cancer causes significant changes in gene transcription and metabolic signaling, resulting in alterations in nutrient acquisition and metabolic substrate selection compared to normal tissues. Exploiting this metabolic reprogramming could potentially lead to targeted therapies for prostate cancer, but there are challenges to overcome. This review outlines the role of various nutrients in prostate tumorigenesis and discusses the factors that contribute to variability in prostate cancer metabolism.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Cell Biology

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling

Annelies Van Hemelryk et al.

Summary: This study presents patient-derived xenografts (PDXs) and matching PDX-derived organoids (PDXOs) as new models for studying castration-resistant prostate cancer (CRPC). These models accurately reflect donor tumors and can predict patient responses to different treatments. The study provides valuable insights into the genomic and transcriptomic features of CRPC and offers a resource for studying treatment-induced resistance mechanisms.

CELLS (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Lilianne Fregeau-Proulx et al.

Summary: The prostate has a unique metabolic profile with a high level of citrate secretion for maintaining male fertility. Studying the metabolic pathways of citrate synthesis in prostate cancer has potential therapeutic implications. The study revealed the involvement of several key nutrients and pathways in the prostate TCA cycle, providing new insights into the metabolic program of citrate synthesis.

MOLECULAR METABOLISM (2022)

添加到收藏夹

Article Oncology

Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies

Herve Lang et al.

Summary: The study established a series of patient-derived xenograft models that recapitulated the molecular heterogeneity of muscle-invasive bladder cancer and upper urinary tract urothelial carcinoma. The findings suggest that these tumors can benefit from similar treatments, such as anti-FGFR and anti-EGFR therapies.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer

Xing Yi Woo et al.

Summary: Patient-derived xenograft models are important preclinical platforms for testing cancer therapeutics. This study describes a repository of genetically and clinically annotated lung cancer PDX models, which have been extensively characterized for histopathologic features, mutational profiles, gene expression, and copy-number aberrations. The genomic profiles of the PDX models are consistent with patient tumors, and these models serve as valuable platforms for translational cancer research.

CANCER RESEARCH (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer

Stephen Y. C. Choi et al.

Summary: This article discusses the urgent need to explore new actionable targets other than the androgen receptor to improve treatment outcomes for castration-resistant prostate cancer. Tumor metabolism is considered a hallmark of cancer and understanding its relationship with androgen receptor signaling, genetic drivers, and the tumor microenvironment is important for identifying metabolic vulnerabilities. The article also provides an overview of current metabolism-based pharmacological strategies for treating castration-resistant prostate cancer.

BIOMOLECULES (2022)

添加到收藏夹

Article Genetics & Heredity

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Xing Yi Woo et al.

Summary: The analysis of copy number alterations in patient-derived xenografts (PDXs) and matched patient tumor samples reveals strong conservation of copy number alterations from patient tumors through late-passage PDXs, without systematic evolution driven by the mouse host. This suggests that PDX models are accurate in representing human cancer and that the mouse host does not significantly impact the copy number alterations during tumor evolution within the PDX model.

NATURE GENETICS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis

Yue Gu et al.

Summary: This study evaluated the potential efficacy of proxalutamide as a novel therapy strategy for prostate cancer. Proxalutamide demonstrated superior inhibitory effects on proliferation and migration of PCa cells, induced apoptosis, reduced lipid accumulation, inhibited de novo lipogenesis, and decreased AR expression. By co-targeting the AR axis and endogenous adipogenesis, proxalutamide offers a promising approach to combat drug resistance and prolong the clinical service life of AR-targeted therapy for PCa.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers

Chia-Lin Chen et al.

Summary: Tumor development requires metabolic adaptations to meet energy demands, with strategies including shifting from oxidative phosphorylation to glycolysis. In prostate cancer, OXPHOS increases compared to normal tissue, presenting therapeutic opportunities for targeting mitochondrial activities. Selective targeting of cancer mitochondria over normal counterparts is a challenge in developing OXPHOS inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Patient-derived xenografts and organoids model therapy response in prostate cancer

Sofia Karkampouna et al.

Summary: Therapy resistance and metastatic processes in prostate cancer remain a challenge, but a new patient-derived xenograft model and organoid system may offer a personalized approach to treatment. This study reveals potential new strategies for screening drug responses and targeting advanced cases with acquired resistance to standard therapies.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer

Paloma Cejas et al.

Summary: Neuroendocrine carcinomas (NECs) arise from different anatomic sites, but share similar histological and clinical features. The epigenetic landscape of NECs converges towards a common state, while distinct subtypes occur within neuroendocrine prostate cancer, contributing to intratumor heterogeneity in clinical samples.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches

Mark P. Labrecque et al.

Summary: The use of androgen deprivation therapy and second-line anti-androgens in prostate cancer has led to the emergence of tumors employing multiple androgen receptor (AR)-dependent and AR-independent mechanisms to resist AR-targeted therapies in castration-resistant prostate cancer (CRPC). While the AR signaling axis remains crucial, understanding the diverse biology of CRPC tumors is crucial for developing innovative treatment strategies. The review discusses the characteristics of CRPC tumors without AR activity, conversion from AR-dependent to AR-independent tumors, and prevalent treatment-emergent phenotypes like amphicrine, AR-low, double-negative, neuroendocrine and small cell phenotypes. It also explores the association between loss of AR activity, tumor plasticity, and the roles of transcription factors, DNA methylation, alternative splicing, and epigenetic modifiers in conversion to neuroendocrine or small cell phenotypes, suggesting only certain CRPC tumors have the propensity for such conversion.

ENDOCRINE-RELATED CANCER (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer

Huan Xu et al.

Summary: Prostate cancer is characterized by abundant fatty acids, leading to rewired fatty acid metabolism during development. Changes to fatty acid metabolism occur systemically and locally in patients, influencing individualized treatments, especially in advanced, castration-resistant cases. These metabolic changes play a critical role in cancer initiation and development, and studying them may lead to potential candidates for treatment and diagnosis.

METABOLITES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer

Lingfan Xu et al.

Summary: This study identifies a metabolic mechanism in prostate cancer where a switch in glutaminase isoforms contributes to therapeutic resistance and disease progression. The expression of GAC leads to increased glutamine utilization and aggressive behavior of tumor cells in the absence of androgen, ultimately impacting treatment outcomes.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Review Oncology

Metabolic reprogramming in prostate cancer

Fahim Ahmad et al.

Summary: While low-risk localized prostate cancer has a good prognosis with effective treatments, metastatic prostate cancer remains incurable and treatment resistance is a major issue. Resistance is primarily driven by tumor heterogeneity, altered genetic signatures, and metabolic reprogramming enabling tumors to adapt to drugs. Understanding prostate cancer metabolism may offer insights into therapy-induced adaptive responses and more durable therapeutic outcomes.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Gail P. Risbridger et al.

Summary: The Melbourne Urological Research Alliance has established patient-derived xenografts of prostate cancer, used for organoids and single-cell RNA-seq, demonstrating the efficacy of PARP inhibitor combination treatments. This preclinical model is crucial for evaluating cancer therapeutics.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer

Huan Xu et al.

Summary: This study reveals the impact of long-chain polyunsaturated fatty acid ELOVL5 on enzalutamide resistance and neuroendocrine differentiation in prostate cancer, providing a potential therapeutic target for treating enzalutamide-resistant NE-like prostate cancer.

CANCERS (2021)

添加到收藏夹

Review Oncology

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer

Paolo Chetta et al.

Summary: Prostate cancer is the second leading cause of cancer-related deaths in the US, with androgen receptor signaling being a major driver of its development and progression. Despite the benefits of second-generation AR signaling inhibitors, resistance mechanisms inevitably occur, highlighting the need for novel strategies to improve PCa survival. Metabolic reprogramming, particularly in lipid metabolism regulated by androgens, plays a key role in resistance to endocrine therapy and targeting PCa metabolic vulnerabilities may represent a potential approach to overcoming resistance. Advances in analytical technologies and metabolic imaging have led to the identification of new prognostic and predictive biomarkers, and non-invasive approaches for monitoring therapy response.

CANCER DRUG RESISTANCE (2021)

添加到收藏夹

Review Oncology

The nuclear export protein XPO1-from biology to targeted therapy

Asfar S. Azmi et al.

Summary: XPO1 plays a crucial role in cellular homeostasis and cancer development, with its inhibitor selinexor clinically validated and approved for multiple myeloma and diffuse large B cell lymphoma treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas

Tony Navas et al.

CANCER RESEARCH (2020)

添加到收藏夹

Editorial Material Oncology

Patient-derived xenograft models-the future of personalised cancer treatment

Jenna Bhimani et al.

BRITISH JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Wassim Abida et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Applications of patient-derived tumor xenograft models and tumor organoids

Go J. Yoshida

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquin Mateo et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Inhibition of mitochondria ATP synthase suppresses prostate cancer growth through reduced insulin-like growth factor-1 secretion by prostate stromal cells

Tomokazu Ohishi et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors

Mohamed E. Salem et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Identification of Potential Key Genes for Pathogenesis and Prognosis in Prostate Cancer by Integrated Analysis of Gene Expression Profiles and the Cancer Genome Atlas

Shuang Liu et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Cell Biology

USP7 Is a Master Regulator of Genome Stability

Gabrielle J. Valles et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

添加到收藏夹

Article Oncology

Monoamine Oxidase A is a Major Mediator of Mitochondria! Homeostasis and Glycolysis in Gastric Cancer Progression

Ling Chen et al.

CANCER MANAGEMENT AND RESEARCH (2020)

添加到收藏夹

Review Oncology

Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer

Takuma Uo et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Neuroendocrine and Aggressive-Variant Prostate Cancer

Nicholas Spetsieris et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

CPT1A Over-Expression Increases Reactive Oxygen Species in the Mitochondria and Promotes Antioxidant Defenses in Prostate Cancer

Molishree Joshi et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies

Loredana Puca et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)

添加到收藏夹

Review Urology & Nephrology

Managing Nonmetastatic Castration-resistant Prostate Cancer

Joaquin Mateo et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma

Bei Gao et al.

METABOLITES (2019)

添加到收藏夹

Review Cell Biology

Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells

Takeshi Namekawa et al.

CELLS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

Yi-Mi Wu et al.

CELL (2018)

添加到收藏夹

Meeting Abstract Oncology

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).

Wassim Abida et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel Clarke et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Cell Biology

Patient-derived xenografts: A platform for accelerating translational research in prostate cancer

Alastair H. Davies et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)

添加到收藏夹

Article Genetics & Heredity

The long tail of oncogenic drivers in prostate cancer

Joshua Armenia et al.

NATURE GENETICS (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina et al.

NATURE MEDICINE (2018)

添加到收藏夹

Review Urology & Nephrology

Cellular plasticity and the neuroendocrine phenotype in prostate cancer

Alastair H. Davies et al.

NATURE REVIEWS UROLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress

Emily M. Schleicher et al.

NUCLEIC ACIDS RESEARCH (2018)

添加到收藏夹

Review Oncology

Molecular Subtypes of Prostate Cancer

Kaveri Arora et al.

CURRENT ONCOLOGY REPORTS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression

Leena Latonen et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer

Stephen Yiu Chuen Choi et al.

CANCER MEDICINE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

Nora M. Navone et al.

PROSTATE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine

Anne T. Collins et al.

PEERJ (2018)

添加到收藏夹

Review Oncology

Targeting ATR in cancer

Emilio Lecona et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Article Oncology

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

Wei Zhang et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

Jennifer L. Bishop et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics

Holly M. Nguyen et al.

PROSTATE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting EZH2 in cancer

Kimberly H. Kim et al.

NATURE MEDICINE (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

Himisha Beltran et al.

NATURE MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer

May-Britt Tessem et al.

PLOS ONE (2016)

添加到收藏夹

Article Oncology

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism

Supriya Shah et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma

Herve Lang et al.

ONCOTARGET (2016)

添加到收藏夹

Review Oncology

Patient-Derived Prostate Cancer: from Basic Science to the Clinic

Gail P. Risbridger et al.

HORMONES & CANCER (2016)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The Ensembl Variant Effect Predictor

William McLaren et al.

GENOME BIOLOGY (2016)

添加到收藏夹

Article Biochemical Research Methods

Sambamba: fast processing of NGS alignment formats

Artem Tarasov et al.

BIOINFORMATICS (2015)

添加到收藏夹

Article Genetics & Heredity

Spatial genomic heterogeneity within localized, multifocal prostate cancer

Paul C. Boutros et al.

NATURE GENETICS (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Oncology

High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development

Dong Lin et al.

CANCER RESEARCH (2014)

添加到收藏夹

Review Oncology

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)

添加到收藏夹

Review Cell Biology

Oncogenic roles of EMT-inducing transcription factors

Alain Puisieux et al.

NATURE CELL BIOLOGY (2014)

添加到收藏夹

Review Oncology

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Manuel Hidalgo et al.

CANCER DISCOVERY (2014)

添加到收藏夹

Article Genetics & Heredity

Pan-cancer patterns of somatic copy number alteration

Travis I. Zack et al.

NATURE GENETICS (2013)

添加到收藏夹

Article Biochemical Research Methods

Xenome-a tool for classifying reads from xenograft samples

Thomas Conway et al.

BIOINFORMATICS (2012)

添加到收藏夹

Review Oncology

Patient-derived tumour xenografts as models for oncology drug development

John J. Tentler et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

Himisha Beltran et al.

CANCER DISCOVERY (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Aaron McKenna et al.

GENOME RESEARCH (2010)

添加到收藏夹

Article Multidisciplinary Sciences

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim et al.

NATURE (2010)

添加到收藏夹

Review Endocrinology & Metabolism

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer

Karen E. Knudsen et al.

TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)

添加到收藏夹

Article Biochemical Research Methods

Fast and accurate short read alignment with Burrows-Wheeler transform

Heng Li et al.

BIOINFORMATICS (2009)

添加到收藏夹

Editorial Material Oncology

From Human to Mouse and Back: Tumorgraft Models Surge in Popularity

Ken Garber

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)

添加到收藏夹

Article Oncology

Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?

Eric A. Klein et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays

Tatiana Popova et al.

GENOME BIOLOGY (2009)

添加到收藏夹

Article Oncology

Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program

RB Shah et al.

CANCER RESEARCH (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.